Lab21 gets license to Celera's CRS7
This article was originally published in Clinica
UK diagnostic testing services provider company Lab21 is set to offer Norwalk, Connecticut-based Celera's CRS7 test for cirrhosis risk in patients with chronic hepatitis C viral (HCV) infection through its sales networks in the UK and Ireland. The personalised CRS7 test, which Lab21 claims is the first clinical test that can predict the probability of a HCV patient progressing to liver fibrosis and cirrhosis, expands the company's presence in the UK and Irish markets for hepatology diagnostics tests. Financial details of the licensing agreement were not disclosed.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.